The U.S. Food and Drug Administration (FDA) has approved the first glucose monitoring system specifically designed for weight loss, developed by the startup Signos. This system integrates Dexcom continuous glucose monitors (CGMs) with artificial intelligence-driven recommendations and is available through monthly plans costing between $129 and $139. Unlike GLP-1 receptor agonists (GLP-1RAs) such as semaglutide, which require injections, this system offers a non-invasive alternative accessible to a broader population. Meanwhile, oral GLP-1 drugs, which are anticipated to replace injectable forms for weight loss, present challenges including higher rates of gastrointestinal side effects like nausea, vomiting, and severe abdominal pain, as reported by patients using drugs like Ozempic. These adverse effects contrast with the convenience of oral administration but remain a concern for physicians and patients. In the UK, there is a shift prioritizing SGLT-2 inhibitors and GLP-1 drugs in diabetes market access, reflecting evolving treatment strategies. The growing use of semaglutide and other weight-loss drugs continues to raise discussions about their broader health impacts, including considerations for people without medical conditions. Despite some opposition from fat acceptance advocates, these medications are recognized as effective interventions for obesity, a condition affecting approximately 5% of Americans.